Results 111 to 120 of about 9,892 (240)

Beneficial effects of tolvaptan on atrial remodeling induced by chronic intermittent hypoxia in rats [PDF]

, 2018
Kai Zhang, Zuowang Ma, Weiding Wang, Ruimeng Liu, Yue Zhang, Meng Yuan, Guangping Li   +6 more
openalex   +1 more source

Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD

Kidney International Reports
Introduction: Tolvaptan has been shown to reduce renal volume and delay disease progression in autosomal-dominant polycystic kidney disease (ADPKD). However, no biomarkers are currently available to guide dose adjustment.
F.J. Roca Oporto, C. Andrades Gómez, G. Montilla Cosano, A. Luna Aguilera, José L. Rocha   +4 more
doaj   +1 more source

L\u2019IPONATRIEMIA NELL\u2019ANZIANO: UNA PROBLEMATICA SEMPRE ATTUALE [PDF]

, 2015
Le alterazioni della concentrazione plasmatica del sodio rappresentano una delle disionie di pi\uf9 frequente riscontro nei pazienti ricoverati e che l\u2019incidenza e la prevalenza aumentano con l\u2019et\ue0.
Barbagallo, M., DOMINGUEZ RODRIGUEZ, L., Schir\uf2, P.   +2 more
core  

The impact of tolvaptan on autosomal dominant polycystic kidney disease – literature review

Studia Medyczne
This article presents current data from international literature on the impact of tolvaptan on autosomal dominant polycystic kidney disease (ADPKD). The authors have reviewed the latest clinical research literature.
Anna Gruszczyńska, Krzysztof Kowalik, Grażyna Dutkiewicz, Anna Rakoczy, Andrzej Modrzejewski   +4 more
doaj   +1 more source

#5783 REAL-LIFE USE OF TOLVAPTAN IN ADPKD: A RETROSPECTIVE ANALYSIS OF A LARGE CANADIAN COHORT [PDF]

, 2023
Luca Calvaruso, Kevin Yau, Pedram Akbari, Fatemeh Nasri, Shirley Xiaoxuan Deng, Saima Khowaja, Ning He, Amirreza Haghighi, Korosh Khalili, York Pei   +9 more
openalex   +1 more source

Impact of continued administration of tolvaptan on cirrhotic patients with ascites [PDF]

, 2018
KODAMA Kazuhisa, KOGISO Tomomi, SAGAWA Takaomi, TANIAI Makiko, TOKUSHIGE Katsutoshi   +4 more
core   +2 more sources

The Vulnerable Phase of Heart Failure [PDF]

, 2018
Butler, Javed, Chioncel, Ovidiu, Collins, Sean, Gracia, Ely, Pang, Peter, Singh, Prabhjot   +5 more
core   +1 more source

Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back [PDF]

, 2016
nephropathy, with an esti-mated prevalence of 1:1000. The disease is characterized by the development of multiple cysts from all nephron segments leading to the enlargement of both kidneys and replacement of normal parenchyma (see [1]).
Devuyst, Olivier, Serra, Andreas, Wang, Xueqi   +2 more
core  

First levetiracetam induced and tolvaptan resistant hyponatremia case

, 2015
Hatem Arı
openalex   +2 more sources

Efficacy of tolvaptan in a patient with right-sided heart failure and renal dysfunction refractory to diuretic therapy [PDF]

, 2014
Yumiko Joko, Nobuhiro Ikemura, Kotaro Miyata, Yasuyuki Shiraishi, Hiroaki Tanaka, Takuo Yoshida, Yukinori Ikegami, Jun Fuse, Munehisa Sakamoto, Yukihiko Momiyama   +9 more
openalex   +1 more source